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Abstract Women with preeclamptic pregnancies have
increased long-term cardiovascular disease (CVD) mor-
tality. We explored this mortality risk among women with
placental abruption, another placental pathology. We used
linked Medical Birth Registry and Death Registry data to
study CVD mortality among over two million women with
a first singleton birth between 1967 and 2002 in Norway
and 1973 and 2003 in Sweden. Women were followed
through 2009 and 2010, respectively, to ascertain subse-
quent pregnancies and mortality. Cox regression analysis
was used to estimate associations between placental
abruption and cardiovascular mortality adjusting for
maternal age, education, year of the pregnancy and coun-
try. There were 49,944 deaths after an average follow-up of
23 years, of which 5453 were due to CVD. Women with
placental abruption in first pregnancy (n = 10,981) had an
increased risk of CVD death (hazard ratio 1.8; 95 % con-
fidence interval 1.3, 2.4). Results were essentially
unchanged by excluding women with pregestational
hypertension, preeclampsia or diabetes. Women with pla-
cental abruption in any pregnancy (n = 23,529) also had a
1.8-fold increased risk of CVD mortality (95 % confidence
interval 1.5, 2.2) compared with women who never expe-
rienced the condition. Our findings provide evidence that
placental abruption, like other placental complications of
pregnancy, is associated with women’s increased risk of
later CVD mortality.
Keywords Placental abruption  Cardiovascular disease 
Women  Mortality
Introduction
Cardiovascular disease (CVD) is the leading cause of death
for women globally [1]. Traditional risk factors and scoring
systems underestimate women’s CVD risk resulting in lost
opportunities for primary prevention [2, 3]. Some preg-
nancy complications may be signs of subclinical endothe-
lial dysfunction or vascular disease and thus provide
insight into a woman’s long-term risk of developing CVD
[4, 5]. It is well established, for example, that women with
a history of preeclampsia have an increased risk of CVD
later in life [6–8]. A previous study in Norway found an
increased risk of cardiovascular disease death among
women with preeclampsia in the first pregnancy, particu-
larly among mothers who did not have any additional
pregnancies [9].
Placental abruption is an uncommon but potentially
serious pregnancy complication involving the premature
detachment of the placental lining from the uterus before
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delivery [10]. Affecting 0.4–1 % of pregnancies, abruption
is a major cause of perinatal death and maternal morbidity.
Fetal survival depends on the severity of the abruption and
gestational age, with perinatal mortality in the range of
9–12 % in high income countries and up to 60 % in set-
tings with inadequate neonatal facilities [10, 11]. The
immediate risks to the mother, depending on severity,
include obstetric hemorrhage, disseminated intravascular
coagulation, renal failure, and in rare cases, death. The
etiology of abruption is not well understood. Non-preg-
nancy associated risk factors are cigarette smoking, alcohol
and drug abuse, chronic hypertension and blood-clotting
disorders; pregnancy-associated risk factors include mul-
tiparity, older age (C35 years) at pregnancy, abdominal
trauma during pregnancy, pregnancy-induced hypertension
and preeclampsia [10, 12, 13]. Like preeclampsia, the
pathophysiological mechanisms of placental abruption are
thought to involve problems in early placental implantation
resulting in uteroplacental ischemia and placental insuffi-
ciency [14–16]. Little is known about long-term health
effects for women who experience abruption. We investi-
gated placental abruption and long-term CVD mortality in
a large, population-based registry study in Norway and
Sweden.
Methods
We used linked data from population-based birth and
cause-of-death registries to study CVD mortality risk
among women giving birth in Norway and Sweden.
Linkage of individual-level data was possible due to the
unique national identity numbers assigned to all legal res-
idents in each country. The Medical Birth Registry of
Norway [17], established in 1967, and the Medical Birth
Register of Sweden [18], established in 1973, are based on
compulsory notification for live and still births. In Norway,
information on all births from 16 completed weeks is
recorded. In Sweden, all live births from 22 completed
weeks are included in the Birth Register. Before 30 June
2008, stillbirths were included from 28 completed weeks.
After that date, stillbirths were included from 22 completed
weeks. The registries include prospectively collected data
on maternal characteristics and medical history, compli-
cations during pregnancy, labor and delivery and condi-
tions of the newborn. Data were recorded in a standard
manner by attending midwives and physicians during
prenatal visits and at delivery and hospital discharge.
Medical conditions, including placental abruption and
other pregnancy complications, were diagnosed by physi-
cians and coded using the International Classification of
Diseases (ICD) (8th revision for years 1967–1998 in Nor-
way and 1973–1986 in Sweden; 9th revision for years
1987–1996 in Sweden; and 10th revision for years
1999–2009 in Norway and 1997–2010 in Sweden). Pla-
cental abruption was defined using ICD-8 codes 632.1 and
651.4, ICD-9 code 641C, and ICD-10 code O45. Mother’s
(and in Norway, father’s) lifetime years of formal educa-
tion (as of 2009 in both countries) were obtained through
linkage to population-based education registers in each
country.
Each woman’s birth history was obtained by linking
births for the period 1967–2009 in Norway and 1973–2010
in Sweden using the mother’s unique national identification
number (Fig. 1). We restricted the study group to women
with a first singleton birth between 1967 and 2002 in
Norway (n = 836,147) and between 1973 and 2003 in
Sweden (n = 1,281,650) in order to be able to identify
women who had second births within 7 years after the first
birth. (In Norway, 95 % of women with two or more births
had their second within 7 years [9].) Maternal (and in
Norway, paternal) deaths were identified by data linkage to
the respective national Cause-of-Death Registry through
December 2009 for Norway and December 2010 for
Sweden. Loss of follow-up due to emigration was low
(\1 %). In addition to total mortality, we analyzed deaths
due to diseases of the circulatory system (ICD-8 and ICD-9
codes 390-459; ICD-10 codes I00-I99). This category was
further divided into deaths from ischemic heart disease
(ICD-8 and ICD-9 codes 410-414; ICD-10 codes I20-I25),
cerebrovascular disease (ICD-8 and ICD-9 codes 430-438
and ICD-10 codes I60-I69), and other circulatory system
diseases (all remaining circulatory system codes). Deaths
from ischemic heart disease and cerebrovascular disease
were combined into one category referred to as ‘‘CVD
deaths’’ for our main analyses. We also examined non-
CVD deaths (all those not included in the circulatory dis-
ease definition above).
We conducted two main sets of analyses. First, we
examined placental abruption in the first pregnancy and
maternal mortality. We analyzed data from Norway and
Sweden separately (n = 836,147 and n = 1,281,650,
respectively) and then pooled the data in combined anal-
yses (n = 2,117,797). We used Cox proportional-hazards
regression to estimate hazard ratios (HRs) and 95 % con-
fidence intervals (CIs). To enable full adjustment for the
effect of age on mortality risk, we used attained age as the
primary time scale with women having delayed entry into
risk sets (left-censored) at the year of their first births [19,
20]. Women were followed until death or until censored at
the cutoff year of 2009 in Norway and 2010 in Sweden.
Models were adjusted for maternal age at first birth (\20,
20–24, 25–29, 30–34, 35–39, 40? years), lifetime years of
maternal education (B9, 10–12, 13–14, 15? years), and
year of first birth (linear term), and, in analyses of com-
bined data, country.
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To remove the possible effects of underlying chronic
disease or other pregnancy conditions on the association
between abruption and maternal mortality, we conducted
analyses restricted to women without the following con-
ditions before or during their first pregnancies: chronic
hypertension, chronic or gestational diabetes mellitus,
preeclampsia, and pregnancy-induced hypertension (avail-
able in Norway only). To assess possible differences in the
associations by number of births and gestational age, we
constructed categorical variables combining the number of
births (one vs. two or more) and pregnancy outcome (term
and preterm with and without placental abruption). Preterm
was defined as delivery in weeks 22 through 36. We
evaluated the statistical significance of interactions by
creating cross-product terms between abruption and the
modifier of interest and using the likelihood ratio test to
compare the fit of models with and without the interaction
term.
In our second set of analyses, we examined mortality
risk in relation to placental abruption in any pregnancy, the
Medical Birth Registry of Norway
1967-2009
836,147 women with first singleton 
birth in 1967-2002
LINKAGE
Norwegian Cause-of-Death Registry
Through 2009
23,009 deaths
Medical Birth Register of Sweden
1973-2010
1,281,650 Women with first singleton 
birth in 1973-2003
LINKAGE
Swedish Cause-of-Death Registry
Through 2010
26,935 deaths
Combined Analyses
1) Abruption in first pregnancy & 
risk of maternal mortality
Main analysis 
2,117,797 women; 
49,944 deaths
Sub-analysis
Restricting to:
Women without chronic hypertension, 
diabetes or preeclampsia
2,022,263 women; 
47,581 deaths
2) Abruption in any pregnancy & 
risk of maternal mortality
(women with singleton births only) 
2,083,732 women; 
49,313 deaths
Father’s analysis: 
Norway only: 
Abruption in first 
pregnancy & risk of 
paternal mortality
821,156 men; 
48,840 deaths
Sub-analysis
Norway only: 
restricting to women 
without pregnancy-
associated or 
chronic
hypertension,
diabetes or 
preeclampsia
782,068 women; 
21,439 deaths
Sub-analysis
Sweden only: 
Adjustment for 
maternal smoking 
1,034,049 women; 
13,946 deaths
Fig. 1 Data sources and numbers of study subjects
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total number of occurrences of abruption, and whether or
not the woman also had preeclampsia in any of her preg-
nancies. These analyses were conducted using combined
data from Norway and Sweden and were restricted to
women with singleton births only n = 2,083,732. We used
Cox proportional-hazards regression with attained age as
the primary time scale; women had delayed entry into risk
sets (left-censored) at the year of their most recent birth
because we were assessing exposures across reproductive
history. The adjustment variables and follow up period
were the same as the first series of analyses described
above.
We used subsets of data available only in Norway or
Sweden to further assess and adjust for possible con-
founding. Using information on 821,156 fathers in Norway,
we examined abruption in first pregnancy and father’s
mortality risk. The objective was to assess the possible role
of confounding by unmeasured social factors. Any asso-
ciation of father’s mortality with abruption would pre-
sumably be unrelated to the physiologic effects of
Table 1 Maternal and
pregnancy characteristics by
occurrence of abruption in first
pregnancy among women with
singleton first births in Norway
1967–2002 and Sweden
1973–2003
Maternal and pregnancy characteristics Abruption in first pregnancy
N = 10,981
No abruption in first pregnancy
N = 2,106,816
Number % Number %
Age at first pregnancy (years)
\20 1170 10.7 218,846 10.4
20–24 3849 35.1 787,053 37.4
25–29 3537 32.2 719,829 34.2
30–34 1755 16.0 292,614 13.9
35–39 567 5.2 76,468 3.6
40? 103 0.9 12,003 0.6
Missinga 0 3
Education (years)
\10 2058 19.1 327,771 15.8
10–12 5146 47.7 975,121 47.1
13–14 1030 9.6 221,670 10.7
15? 2547 23.6 547,661 26.4
Missinga 200 34,593
Place of birth
Native to Norway or Sweden 9773 89.7 1,862,732 88.9
Other Nordic 402 3.7 77,169 3.7
Other 726 6.7 156,138 7.5
Missinga 80 10,777
Parity by end of follow-up
One child 2366 21.6 370,494 17.6
Two or more 8615 78.4 1,736,322 82.4
Pre-gestational hypertensionb 43 0.4 4041 0.2
Pre-gestational diabetesb 45 0.4 5223 0.4
Preterm delivery 5263 49.8 122,544 6.0
Missinga 404 50,170
Gestational diabetesb 33 0.3 6234 0.3
Preeclampsiab 1106 10.1 80,868 3.8
Pregnancy-related hypertensionb,c 118 2.5 14,266 1.7
Smoked during any pregnancyd 1792 34.7 257,450 24.6
Missing 1087 229,132
a Missing values\4 %
b Status during first pregnancy
c Norway only
d Sweden only, women with singleton births only, smoking information available 1983-onward, 18 %
missing values
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pregnancy. We used the same selection criteria and ana-
lytic strategy as for mothers, with father’s attained age as
the underlying time variable in the Cox proportional haz-
ards models, left-censoring at the year of first delivery, and
adjustment for father’s age at the birth (\20, 20–24, 25–29,
30–34, 35–39, 40? years), year of first birth (linear term),
and father’s education (9 categories).
In Sweden, information on maternal smoking was
ascertained by midwives at the time of the first prenatal
care visit (occurring before the 15th week of gestation in
over 95 % of the pregnancies) and was available in the
Medical Birth Register from 1983-onward. For our analysis
of mortality risk, we were interested in women’s smoking
status and not the level of smoking in any particular
pregnancy. To estimate this, we grouped women as non-
smokers (i.e., non-daily smokers) and smokers (i.e., daily
smokers) at the first prenatal visit. To maximize the use of
the available data, we examined smoking across all of each
woman’s pregnancies and categorized women as ever or
never smokers, thus avoiding missing data for the women
with first pregnancies before 1983 but who had later
pregnancies with smoking information. Among the
1,034,049 women with smoking data using this strategy,
we assessed possible confounding by comparing estimates
from models including and excluding the smoking variable
in analyses examining abruption in any pregnancy and risk
of maternal mortality.
Results
Placental abruption in first pregnancy
Among the 2,117, 797 women who had first deliveries
during the study period, 10,981 (0.5 %) had placental
abruption (Table 1). The mean follow up time was
25 years in Norway, 22 years in Sweden, and 23 years
(range 1–42 years) in the combined material with a total of
48,786,382 person-years at risk. There were 5453 CVD
deaths out of a total of 49,994 deaths during the follow up
period (22,885 in Norway and 26,760 in Sweden). The
median age at death was 48 years overall and 51 years for
CVD deaths.
Associations between abruption in first pregnancy and
mortality outcomes were generally similar for Norway and
Sweden (Table 2); results of the combined analyses are
reported here. Compared with women who did not expe-
rience placental abruption in first pregnancy, those who
experienced placental abruption had an increased risk of
CVD mortality (HR 1.8; 95 % CI 1.3, 2.4). Risks were
similar for the sub-categories of ischemic heart disease
(HR 2.0; 1.4, 2.9) and cerebrovascular disease (HR 1.6;
1.0, 2.4). Women with abruption also had a small increased
risk of dying from non-CVD disease (HR 1.2; 1.0, 1.3).
Increased risk of CVD mortality persisted after excluding
women with chronic hypertension, chronic or gestational
diabetes, preeclampsia, and pregnancy-related hyperten-
sion (Table 3).
For women with two or more pregnancies, abruption in
the first pregnancy was associated with an increased risk of
CVD mortality (HR 2.1; 1.5, 2.9) (Table 4). For women
with one lifetime pregnancy, the increased risk of CVD
mortality associated with abruption (HR 2.6; 1.5, 4.3) was
only marginally increased above the CVD mortality risk
associated with having only one pregnancy (HR 1.9; 1.8,
2.1) (reference group women with two or more pregnancies
and no abruption in first pregnancy). The interaction
between number of pregnancies and abruption for CVD
mortality was not statistically persuasive (p value = 0.16).
The association between abruption and CVD mortality was
present mainly in women who had preterm deliveries (HR
2.3; 1.6, 3.3 for abruption in preterm; HR 1.3; 0.8, 2.2 for
abruption in term), however the interaction between pre-
term delivery and abruption for CVD mortality was not
statistically persuasive (p value = 0.86).
Placental abruption in any pregnancy
In analyses of placental abruption in any pregnancy, the
mean follow up was 23 years (range 1–42 years) among
2,083,732 women, contributing to 48,018,129 person years
at risk. A total of 23,529 women or 1.1 % of the study
population had placental abruption in any pregnancy. There
were 5385 CVD deaths out of a total of 49,313 deaths
during the follow up period. Compared with women who
never experienced placental abruption, women who had
placental abruption in at least one pregnancy had a 1.8-fold
increased risk of CVD mortality (Table 5). The HR was
slightly higher among the 782 women who had abruption
in 2 or more pregnancies (HR 2.2; 0.8, 6.0) based on only 5
CVD deaths in the exposed group. Women who had
abruption in 2 or more pregnancies also had an increased
risk of dying from a non-CVD cause (HR 1.6; 1.1, 2.5). In
conjoint analyses of placental abruption and preeclampsia
in any pregnancy, there were increased risks of CVD
mortality among women who had placental abruption only
(HR 1.8; 1.4, 2.2), preeclampsia only (HR 1.9; 1.7, 2.1),
and women experiencing both conditions in either the same
or different pregnancies (HR 3.0; 1.9, 4.8) compared with
women who had experienced neither.
Father’s analysis
In the Norwegian data, the association between placental
abruption in the first delivery and father’s CVD mortality
Placental abruption and long-term maternal cardiovascular disease mortality: a population…
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Table 3 Placental abruption in first pregnancy and long-term mortality risk among women with singleton first births in Norway 1967–2002 and
Sweden 1973–2003
Condition of first
pregnancy
Number of
women
Cardiovascular disease deaths Non-cardiovascular disease deathsa Total deaths
Number Adjusted hazard ratio
(95 % confidence
interval)b
Number Adjusted hazard ratio
(95 % confidence
interval)b
Number Adjusted hazard ratio
(95 % confidence
interval)b
Main analysis
Placental abruption
No 2,106,816 5398 1.0 (Referent) 40,572 1.0 (Referent) 49,583 1.0 (Referent)
Yes 10,981 55 1.8 (1.3, 2.4) 273 1.2 (1.0, 1.3) 361 1.3 (1.1, 1.4)
Sub-analyses
Excluding women with chronic hypertension, pre-pregnancy or gestational diabetes, preeclampsia
Placental abruption
No 2,012,488 4941 1.0 (Referent) 38,757 1.0 (Referent) 47,264 1.0 (Referent)
Yes 9775 45 1.7 (1.2, 2.3) 244 1.2 (1.0, 1.3) 317 1.3 (1.1, 1.4)
Norway only: excluding women with the above conditions plus pregnancy-related hypertension
Placental abruption
No 777,977 2212 1.0 (Referent) 17,868 1.0 (Referent) 21,290 1.0 (Referent)
Yes 4091 23 1.8 (1.2, 2.8) 117 1.2 (1.0, 1.4) 149 1.3 (1.1, 1.5)
a Excluding all circulatory conditions
b Adjusted for mother’s age at first birth, mother’s education, birth year of child, and in analyses of combined data, country
Table 4 Placental abruption in first pregnancy and long-term mortality risk by number of pregnancies among women with singleton first births
in Norway 1967–2002 and Sweden 1973–2003
Condition of first pregnancy Number of
women
Cardiovascular disease
deaths
Non-cardiovascular disease
deathsa
Total deaths
Number Adjusted
hazard
ratio (95 %
confidence
interval)b
Number Adjusted
hazard
ratio (95 %
confidence
interval)b
Number Adjusted
hazard
ratio (95 %
confidence
interval)b
Placental abruption by no. lifetime pregnancies
No abruption—2? pregnancies 1,736,322 3429 1.0 (Referent) 27,529 1.0 (Referent) 33,329 1.0 (Referent)
Abruption—2? pregnancies 8615 35 2.1 (1.5, 2.9) 172 1.2 (1.0, 1.4) 227 1.3 (1.1, 1.5)
No abruption—1 pregnancy 370,494 1969 1.9 (1.8, 2.1) 12,835 1.7 (1.7, 1.7) 16,254 1.7 (1.7, 1.8)
Abruption—1 pregnancy 2366 20 2.6 (1.5, 4.3) 100 2.0 (1.6, 2.5) 134 2.2 (1.8, 2.6)
Interaction abruption 9 no. of
pregnancies
p value = 0.16 p value = 0.97 p value = 0.84
Placental abruption by preterm
No abruption—term 1,934,102 4632 1.0 (Referent) 36,263 1.0 (Referent) 44,230 1.0 (Referent)
Abruption—term 5314 21 1.3 (0.8, 2.2) 122 1.1 (0.9, 1.3) 161 1.2 (1.0, 1.4)
No abruption—preterm 122,544 600 1.8 (1.7, 2.0) 2968 1.2 (1.2, 1.3) 3953 1.3 (1.3, 1.4)
Abruption—preterm 5263 30 2.3 (1.6, 3.3) 138 1.3 (1.1, 1.5) 184 1.4 (1.2, 1.6)
Interaction abruption 9 preterm p value = 0.86 p value = 0.64 p value = 0.29
a Excluding all circulatory conditions
b Adjusted for mother’s age at first birth, mother’s education, birth year of child and country
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was small and did not reach statistical significance (HR
1.2; 0.9, 1.5).
Adjustment for maternal smoking
In the subset of Swedish data with available smoking infor-
mation from 1983-onward, maternal smoking was associ-
ated with both non-CVD mortality (HR 1.7; 1.7, 1.8) and
CVD mortality (HR 2.9; 2.5, 3.3). Without adjustment for
smoking, the association between abruption in any preg-
nancy and risk of maternal CVD mortality was HR = 2.0
(1.3, 2.3) after adjusting formaternal age, education and year
of first birth. Further adjustment for maternal smoking
attenuated this association (HR 1.7; 1.2, 2.5).
Discussion
In this large, population-based study, women with pla-
cental abruption in the first or a later pregnancy had a 1.8-
fold increased risk of CVD mortality later in life. The
magnitude of the association is similar to that of current
smoking and CVD mortality in women [21, 22]. This study
adds to the growing evidence that pregnancy complications
may predict later CVD and help target women for primary
prevention [23]. It is unclear whether the metabolic,
inflammatory and hemodynamic demands of pregnancy
unmask underlying phenotypic susceptibility to CVD
expressed through pregnancy complications or if the
complicated pregnancy itself induces vascular damage or
inflammatory or other responses that increase CVD risk
[24]. Following a complicated pregnancy, postpartum
referral by obstetricians to primary-care physicians or
cardiologists for monitoring and controlling CVD risk
factors would allow women of child-bearing age to begin
preventive efforts early in life and reduce the risk of CVD.
The American Heart Association recently incorporated
history of preeclampsia, gestational diabetes, and preg-
nancy-induced hypertension into its CVD risk-assessment
guidelines for women [25]. Placental abruption should be
considered for inclusion as an additional risk factor.
There was a suggestion in our data of a stronger effect of
abruption among women who had two or more pregnancies
and those with preterm deliveries. However, these inter-
actions lacked statistical strength, which limits our ability
to interpret them. Women with only one pregnancy already
have a strongly increased risk of CVD mortality (as has
been reported earlier [9]), which may make the further
influence of abruption difficult to detect. Vaginal bleeding
caused by placental abruption is associated with a high risk
of preterm delivery [26]. The occurrence of abruption may
necessitate or provoke the delivery of the infant early in
gestation [27]. In our study, about half of the women with
abruption in first pregnancy had pregnancies ending in
preterm delivery. Preterm delivery itself is associated with
increased risk of maternal CVD [28, 29], suggesting that it
Table 5 Placental abruption in any pregnancy and long-term mortality risk among women with first singleton births in Norway 1967–2002 and
Sweden 1973–2003
Number Cardiovascular disease deaths Non-cardiovascular disease deathsa Total deaths
Number Adjusted hazard
ratio (95 %
confidence
interval)b
Number Adjusted hazard
ratio (95 %
confidence
interval)b
Number Adjusted hazard
ratio (95 %
confidence
interval)b
Placental abruption
Never 2,060,203 5272 1.0 (Referent) 39,557 1.0 (Referent) 48,573 1.0 (Referent)
Ever 23,529 113 1.8 (1.5, 2.2) 562 1.2 (1.1, 1.3) 740 1.3 (1.2, 1.4)
No. of times
Never 2,060,203 5272 1.0 (Referent) 39,557 1.0 (Referent) 48,573 1.0 (Referent)
1 22,747 108 1.8 (1.5, 2.2) 535 1.2 (1.1, 1.3) 706 1.3 (1.2, 1.4)
2? 782 5 2.2 (0.8, 6.0) 27 1.6 (1.1, 2.5) 34 1.7 (1.2, 2.5)
Placental abruption and preeclampsia/eclampsia
Never had either 1,950,617 4790 1.0 (Referent) 37,751 1.0 (Referent) 46,026 1.0 (Referent)
Placental abruption only 20,701 95 1.8 (1.4, 2.2) 505 1.2 (1.1, 1.3) 654 1.3 (1.2, 1.4)
Preeclampsia only 109,586 482 1.9 (1.7, 2.1) 1806 0.9 (0.9, 1.0) 2547 1.1 (1.0, 1.1)
Both 2828 18 3.0 (1.9, 4.8) 57 1.1 (0.8, 1.4) 86 1.3 (1.1, 1.7)
Excluding women with multiple gestations in any pregnancy
a Excluding all circulatory conditions
b Adjusted for mother’s age at first birth, mother’s education, birth year of child and country
L. A. DeRoo et al.
123
may be in the causal pathway for the association between
abruption and CVD mortality.
The results of the father’s analysis provide some
assurance that our main findings in mothers were not pri-
marily due to unmeasured confounding of lifestyle vari-
ables. There was evidence of a small increased risk of
paternal CVD mortality for first-pregnancy abruption
(although confidence intervals included one), suggesting
that our findings may have a small degree of confounding
by unmeasured social factors or CVD risk factors, such as
cigarette smoking, that have a high concordance in partners
[30, 31]. In our sub-analysis of Swedish data, adjustment
for maternal smoking left most of the association between
abruption and maternal CVD mortality, although our
smoking data were limited to information collected at the
first prenatal care visit and residual confounding is still
possible. To the extent that smokers were misclassified in
our sub-analysis, the association between abruption and
risk of CVD mortality may be overestimated.
The increased risk for non-CVD mortality among
women who experienced abruption in two or more preg-
nancies is notable. Among the 34 women with recurrent
abruption who died of non-CVD causes, 18 % had drug or
alcohol-related deaths compared with only 6 % of the
deaths among women without abruption. Injury-related
deaths, including suicide, were also increased (29 vs.
16 %), but not cancer deaths (32 vs. 52 %). This suggests
that the increased risk of non-CVD mortality among
women with recurrent abruption was due, at least in part, to
drug or alcohol abuse, factors also related to increased risk
of abruption.
The prevalence of abruption in our study is similar to
that of other epidemiologic studies relying on clinical
diagnosis. Placental abruption has not been validated in the
Norway Birth Registry, but a 1986 validation study in
Sweden found good correspondence between the diagnosis
of abruption as reported by ICD codes in the birth registry
and the description of clinical abruption documented in
individual delivery records [32]. In the United States, two
validation studies comparing state birth certificates with
medical records found [99 % specificity and moderate
sensitivity for abruption, as would be expected for a rare
condition [33, 34]. This suggests that studies using vital
statistics registries are subject to under-ascertainment of
rare conditions such as abruption but have negligible
numbers of false positives. With the assumption that
exposure misclassification is non-differential in regard to
outcome, which seems reasonable in our study because the
collection of exposure data in registries predated the out-
come, any bias produced by exposure misclassification
would tend to be toward the null.
The strengths of this study include the use of population-
based registry data from two Nordic countries, which
enabled a large study size, prospective data collection, the
study of complete reproductive history, and nearly com-
plete ascertainment of mortality. Limitations of the study
include a lack of detailed information on underlying car-
diovascular risk factors before and after pregnancy. We
also lacked information on the severity of the abruption and
could not differentiate between mild cases and the more
serious manifestations. Even in our study of over 2 million
women, we had small numbers of women for some of the
exposures of interest, particularly recurrent abruption,
which limited our statistical power in some analyses.
Although we lacked information on maternal smoking for
the full study, we were able to use available Swedish data
to adjust for smoking in sub-analyses. However, there is
likely some misclassification of smoking in these analyses;
for example, women who smoked either before or after
their pregnancies but abstained during pregnancy would
have been misclassified as non-smokers in our study. Even
with an average of 23 years of follow-up, the women in
this study were relatively young at the end of follow up.
The CVD deaths that occurred at a relatively young age
among women with abruption may reflect the most severe
cases of the condition, and therefore the associations
between abruption and risk of CVD mortality may atten-
uate as the follow up period increases over time, as
observed in a study of preeclampsia [9].
Two previous studies examined placental abruption and
long-term maternal CVD mortality. A large registry-based
study in Denmark of 782,287 women with singleton
deliveries 1978–2007 (7684 with abruption) and a median
follow-up of 14.8 years found a weakly increased risk of
CVD mortality for women with abruption (HR 1.23; 0.78,
1.93) [35]. Their CVD endpoint differed from ours; along
with a CVD cause of death stated in the Cause of Death
Registry, they also included a first clinical diagnosis of
CVD (e.g., de novo hypertension) within 1 week prior to
death. If their broader definition resulted in misclassifica-
tion of non-CVD deaths as CVD deaths, then the resulting
bias would tend to be towards the null. An Israeli study
examined CVD mortality among 47,585 women (653 with
abruption) who gave birth in a large medical center during
1988–1999 with a median follow up of 13.8 years [36].
They found an increased risk of CVD mortality for women
with abruption (HR 4.3; 1.1–18.6). This hospital-based
study lacked information on CVD mortality outside of the
medical center and the small numbers of outcomes (only 6
CVD deaths among exposed women) contributed to
imprecise estimates. Our use of registry data from two
countries allowed population-based ascertainment of CVD
deaths and provided a larger sample of women and longer
follow-up time than these previous studies.
In summary, we found evidence that placental abrup-
tion, like other placental complications of pregnancy, is
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associated with women’s increased risk of later CVD
mortality. Pregnancy complications occur at an early phase
of life when targeted prevention may allow women to
avoid CVD through lifestyle changes or preventive medi-
cine. It is currently unknown whether traditional prevention
measures will be effective in reducing long-term CVD risk
in this population of women [37]. The feasibility of
changing the course of women’s CVD risk after placental
complications of pregnancy should be explored.
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